QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$289.44
+3.94 (+1.38%)
(As of 01/30/2023 12:13 PM ET)
Add
Compare
Today's Range
$284.07
$289.44
50-Day Range
$279.72
$313.00
52-Week Range
$181.00
$320.00
Volume
108,593 shs
Average Volume
373,542 shs
Market Capitalization
$20.10 billion
P/E Ratio
1,206.00
Dividend Yield
N/A
Price Target
$309.23

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
8.6% Upside
$309.23 Price Target
Short Interest
Bearish
3.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.57mentions of Insulet in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$8.51 M Sold Last Quarter
Proj. Earnings Growth
17.24%
From $0.87 to $1.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

554th out of 1,049 stocks

Surgical & Medical Instruments Industry

55th out of 105 stocks


PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet Has Potential To Gain More Than Analysts Are Forecasting
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Invest in Brooklyn Gin: Hot craft spirits opportunity
Get in on an award winning company in the fast growing craft spirits marketpixel
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
Is Insulet About to Continue Its Move Higher?
2 Best Medical Device Stocks for 2023
Why Insulet Stock Is Skyrocketing Today
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$309.23
High Stock Price Forecast
$345.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+6.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
1.68%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.09 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,824,000
Market Cap
$20.10 billion
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • James R. Hollingshead
    President, Chief Executive Officer & Director
  • Prem Singh
    Senior Vice President-Global Operations
  • Wayde Dwight McMillan
    Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly
    Senior Vice President & Medical Director
  • Michael P. Spears
    Senior VP-Quality, Regulatory Affairs & Compliance













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

14 brokerages have issued 12-month price objectives for Insulet's shares. Their PODD share price forecasts range from $245.00 to $345.00. On average, they expect the company's stock price to reach $309.23 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD shares have decreased by 3.0% and is now trading at $285.50.
View the best growth stocks for 2023 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PODD earnings forecast
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Thursday, November, 3rd. The medical instruments supplier reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.28. The medical instruments supplier had revenue of $340.80 million for the quarter, compared to analysts' expectations of $311.84 million. Insulet had a net margin of 1.35% and a trailing twelve-month return on equity of 18.19%.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $341.55 million-$350.78 million, compared to the consensus revenue estimate of $328.46 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.65%), AEGON ASSET MANAGEMENT UK Plc (0.27%), Beacon Investment Advisory Services Inc. (0.27%), Scout Investments Inc. (0.22%), Stephens Investment Management Group LLC (0.09%) and Eastern Bank (0.05%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $285.50.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $19.83 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.24 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,300 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 1/30/2023 by MarketBeat.com Staff